The management believes, that on account of ramp-up of existing products, Fermion contract, and potential commercialisation ...

Extension of PLI scheme, more incentives to improve ease of doing business and Prioritizing Research and Development are ...

India's Jubilant Pharmova reported a 51% jump in third-quarter profit on Friday, driven by a strong demand for its drugs with ...

While Budget 2025 is expected to bring refinements that could further elevate certain industries, a critical shift in the ...

"We thank our stockholders for their support through our time as a public company and the duration of this process,” said Nick Green, president and CEO of Avid Bioservices. "We look forward to ...

Piramal Pharma launched Chlorpromazine Hydrochloride in the US last week. The company reported a 14% growth in its complex ...

Study Forecasts 7.0% CAGR, with the CDMO Market Expanding from $136.6 Billion in 2024 to $191.6 Billion by 2029, Fueled by Increased Demand for Outsourced Drug Development and Manufacturing.Boston, ...

Although Lonza posted slightly lower sales than analysts had expected in 2024, the Swiss CDMO suggested in its year-end ...

Experts say budget should focus on expanding the scheme to encompass green energy, advanced textiles, space tech and ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teva ...

India's pharmaceutical industry is set for growth, driven by strong market players, global reputation, and evolving trends.

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...